Better Health for All

Iovance Biotherapeutics' core business is the development and delivery of TIL therapies for cancer patients, with Amtagvi being the first FDA-approved T-cell therapy for a solid tumor.

The entire business is devoted to health improvement, and clinical trial data for Amtagvi shows a 32% overall response rate for unresectable/metastatic melanoma, including 4% complete responses and 27% partial responses in 73 patients. The company has no revenue from products with well-established negative health outcomes. Common side effects of Amtagvi include chills, fever, low white blood cells, fatigue, anemia, irregular heartbeat, rash, low blood pressure, and diarrhea, which are notable safety incidents. The company's R&D expenses were $76.9M in Q1 2025, with a net loss of $116.2M, indicating that over 66% of its total product revenue ($49.3M) is invested in R&D, focused on improving health outcomes and developing next-generation therapies. The company holds a patent portfolio covering TIL compositions, methods of treatment, and manufacturing, with exclusivity expected through 2042. While IovanceCares offers a copay support program for commercially insured patients and a patient assistance program for uninsured/underinsured patients, no specific pricing details or cost-plus data are provided to assess affordability relative to production cost or median income. Similarly, while the company targets ATCs in underserved areas, no specific data on the percentage of vulnerable populations reached is available. The company clearly states potential side effects and the need for hospital-based administration for Amtagvi. The company's products are not associated with addiction potential or food/nutrition, and there is no evidence of preventative health measures.

Fair Money & Economic Opportunity

Iovance Biotherapeutics is a biotechnology company focused on developing and commercializing cancer immunotherapies.

Its core business does not involve lending, insuring, moving, or storing money for consumers. Therefore, the company does not offer consumer credit products, manage customer finance data, or engage in financial services that would generate APRs, fees, or loan books. Consequently, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility for financial data, fair lending compliance, wealth building outcomes from financial products, profit reinvestment in community finance, financial literacy initiatives, debt burden ratio, geographic inclusion for banking services, and product simplicity for financial products, are not applicable to its operations.

Fair Pay & Worker Respect

Iovance Biotherapeutics receives a score of -10, indicating slight misalignment with the value of Fair Pay & Worker Respect. A 2023 OSHA penalty of $11,162 for a workplace safety or health violation is documented.

Glassdoor reviews show mixed employee sentiment, with some praising pay and benefits, while others criticize management, lack of guidance, and high turnover rates. , , , The overall Glassdoor rating is 3.0 out of 5, with only 36% of employees recommending the company to a friend. , The CEO approval rating is also low at 39%. A 2020 report indicates a CEO-to-median employee pay ratio of 24:1. While this ratio is relatively low, the negative employee reviews and safety violation suggest areas for improvement. There is insufficient evidence to assess living wage coverage, collective bargaining share, pay equity ratio, worker engagement score, insecure contract share, or health insurance coverage. , ,

Fair Trade & Ethical Sourcing

No specific, quantitative, or concrete evidence was found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. Information regarding fair trade certifications, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clauses in supplier contracts, materials risk index, or supplier diversity spend is not available.

While a Code of Conduct exists and applies to external business partners, the articles do not specify the percentage of supplier contracts that include enforceable ethical-sourcing clauses.

Honest & Fair Business

Iovance Biotherapeutics had one financial restatement in May 2025, which was related to its Q1 2025 results and full-year 2025 revenue guidance.

The company is currently under investigation for securities fraud violations, with lawsuits filed alleging misleading statements about its treatment centers and capacity, which led to a significant decline in stock price and a reduction in 2024 revenue guidance. The company has a whistle-blower protection policy that outlines investigation and disciplinary action procedures, and an anti-corruption policy that includes a Code of Conduct and policies related to gifts and promotional materials, specifically mentioning compliance with California Health & Safety Code §§ 119400-119402 and an annual aggregate limit of $2,000 per California healthcare professional for specified items.

Kind to Animals

Iovance Biotherapeutics, Inc. engages in animal testing for medical analysis and clinical research, as stated in their own report, specifically for potential longer engraftment and better tumor control.

No quantitative data on the volume of animals used in testing or details on alternative testing methods are provided. There is no information available regarding cruelty-free certifications, humane certifications for operations, wildlife conservation impact, ethical input substitution, supplier audits, cage-free sourcing, R&D investment in animal-free technologies, animal agriculture ethics, animal-free R&D collaborations, or public policy engagement.

No War, No Weapons

Iovance Biotherapeutics has no military contracting activities.

The company also has no exposure to controversial weapons.

Planet-Friendly Business

The company has no specific regulatory actions, violations, fines, or compliance issues mentioned in the provided articles.

Additionally, IOVANCE.US does not publicly disclose carbon emissions or reduction targets, nor does it participate in any tracked reduction initiatives.

Safe & Smart Tech

The company reports no specific data breach details and states it is not aware of any material risks from cybersecurity threats.

It has a security awareness program for employees and performs security testing, including a vulnerability management program with scanning and penetration testing. No specific incidents of unauthorized data use have been reported. The privacy policy states that data is collected only as necessary for stated purposes, with retention periods based on need and applicable law. Users can update their information and may have access, correction, or deletion rights, subject to verification. The company's privacy policy mentions compliance with GDPR, CCPA, PIPEDA, and the Australian Federal Privacy Act, and it operates in a regulated biopharmaceutical sector.